Laboratoires Majorelle

Based in France, Laboratoires Majorelle operates in women's and sexual health, offering innovative healthcare solutions focused on gynecology, urology, and infectious diseases. Laboratoires Majorelle, founded in 2012 in Paris, France, specializes in developing healthcare products for women's health and sexual well-being. The company was founded by Guillaume Glaoui, who serves as both CEO and founder. In April 2021, EW Healthcare Partners acquired a majority stake in Laboratoires Majorelle to enhance its product portfolio and commercial infrastructure.

The company has completed one deal as of the most recent update. Laboratoires Majorelle specializes in women's health and sexual health, offering a range of innovative healthcare products focused on gynecology, urology, and infectious diseases. Their core product offerings include medical solutions for erectile dysfunction, treatments for sexually transmitted infections (STIs), and a line of consumer health products like hand sanitizers and lip care. Additionally, they provide free condoms for young individuals under 26, promoting safe sexual health practices.

The products are designed to be effective and safe, catering to both health professionals and end-users, which includes women and men facing specific health challenges. Laboratoires Majorelle's offerings are primarily distributed across the French healthcare market, aligning with the country’s social security system for coverage of certain products, thereby enhancing accessibility for patients and healthcare providers. Laboratoires Majorelle generates revenue through direct sales of its innovative healthcare products to health professionals and consumers, establishing partnerships within the medical community. Their transaction structure is centered around B2B relationships, where healthcare providers purchase medical solutions and consumer health products for distribution in pharmacies and clinics.

The company's flagship products, including treatments for erectile dysfunction and STIs, are made available through these channels, ensuring compliance with regulatory requirements. The pricing strategy is aligned with the social security framework in France, which facilitates the provision of certain products at no cost to eligible populations, such as free condoms for individuals under 26. This structured approach fosters an environment of accessibility while catering to the specific needs of their diverse client base. Laboratoires Majorelle aims to extend its product portfolio and further build its commercial infrastructure in France following the acquisition in April 2021.

The company plans to launch new products focused on women's health and sexual wellness in the near future, with specific release dates yet to be announced. Additionally, they are exploring opportunities to expand into new markets within Europe, targeting a broader demographic to increase their market presence. The recent acquisition will support these initiatives, enhancing their capability to grow as a key specialty pharma player in the women's health and urology sectors.